236 related articles for article (PubMed ID: 17845136)
1. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.
Hedner U; Ezban M
Annu Rev Med; 2008; 59():29-41. PubMed ID: 17845136
[TBL] [Abstract][Full Text] [Related]
2. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
3. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa: its background, development and clinical use.
Hedner U
Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of factor VIIa in the treatment of coagulopathies.
Hedner U
Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():77-85. PubMed ID: 16673269
[TBL] [Abstract][Full Text] [Related]
6. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Veldman A; Hoffman M; Ehrenforth S
Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
[TBL] [Abstract][Full Text] [Related]
7. rFVIIai in Acute Coronary Syndromes.
Sorensen BB; Hedner U; Erhardtsen E
Semin Vasc Med; 2003 May; 3(2):199-204. PubMed ID: 15199483
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action, development and clinical experience of recombinant FVIIa.
Hedner U
J Biotechnol; 2006 Aug; 124(4):747-57. PubMed ID: 16697480
[TBL] [Abstract][Full Text] [Related]
10. First 20 years with recombinant FVIIa (NovoSeven).
Hedner U; Lee CA
Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
Hedner U; Brun NC
Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
[TBL] [Abstract][Full Text] [Related]
12. History of rFVIIa therapy.
Hedner U
Thromb Res; 2010 Apr; 125 Suppl 1():S4-6. PubMed ID: 20188400
[TBL] [Abstract][Full Text] [Related]
13. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
He S; Blombäck M; Jacobsson Ekman G; Hedner U
J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
[TBL] [Abstract][Full Text] [Related]
14. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Augustsson C; Persson E
Blood; 2014 Nov; 124(20):3172-4. PubMed ID: 25232061
[TBL] [Abstract][Full Text] [Related]
15. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
[TBL] [Abstract][Full Text] [Related]
16. The role of tissue factor and factor VIIa in hemostasis.
Mackman N
Anesth Analg; 2009 May; 108(5):1447-52. PubMed ID: 19372318
[TBL] [Abstract][Full Text] [Related]
17. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
18. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
Hedner U; Erhardtsen E
Ann Med; 2000 Dec; 32 Suppl 1():68-72. PubMed ID: 11209985
[TBL] [Abstract][Full Text] [Related]
19. [Use of recombinant activated factor VII].
Reingardiene D; Lazauskas R
Medicina (Kaunas); 2009; 45(3):248-53. PubMed ID: 19357455
[TBL] [Abstract][Full Text] [Related]
20. FVIIa as therapeutic agent in hemophilia and beyond.
Hedner U
Front Biosci (Elite Ed); 2012 Jan; 4(4):1210-23. PubMed ID: 22201947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
